Literature DB >> 2668333

Proteolytic inactivation of plasma C1- inhibitor in sepsis.

J H Nuijens1, A J Eerenberg-Belmer, C C Huijbregts, W O Schreuder, R J Felt-Bersma, J J Abbink, L G Thijs, C E Hack.   

Abstract

Activation of both the complement system and the contact system of intrinsic coagulation is implicated in the pathophysiology of sepsis. Because C1 inhibitor (C1-Inh) regulates the activation of both cascade systems, we studied the characteristics of plasma C1-Inh in 48 patients with severe sepsis on admission to the Intensive Care Unit at the Free University of Amsterdam. The ratio between the level of functional and antigenic C1-Inh (functional index) was significantly reduced in the patients with sepsis compared with healthy volunteers (P = 0.004). The assessment of modified (cleaved), inactive C1-Inh (iC1-Inh), and complexed forms of C1-Inh (nonfunctional C1-Inh species) revealed that the reduced functional index was mainly due to the presence of iC1-Inh. On SDS-PAGE, iC1-Inh species migrated with a lower apparent molecular weight (Mr 98,000, 91,000, and 86,000) than native C1-Inh (Mr 110,000). Elevated iC1-Inh levels (greater than or equal to 0.13 microM) were found in 81% of all patients, sometimes up to 1.6 microM. Levels of iC1-Inh on admission appeared to be of prognostic value: iC1-Inh was higher in 27 patients who died than in 21 patients who survived (P = 0.003). The mortality in 15 patients with iC1-Inh levels up to 0.2 microM was 27%, but in 12 patients with plasma iC1-Inh exceeding 0.44 microM, the mortality was 83%. The overall mortality in the patients with sepsis was 56%. We propose that the cleavage of C1-Inh in patients with sepsis reflects processes that play a major role in the development of fatal complications during sepsis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2668333      PMCID: PMC548902          DOI: 10.1172/JCI114185

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  61 in total

1.  Peripheral vascular resistance in septic shock: its relation to outcome.

Authors:  A B Groeneveld; J J Nauta; L G Thijs
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

2.  Expression of functional human C1 inhibitor in COS cells.

Authors:  E Eldering; J H Nuijens; C E Hack
Journal:  J Biol Chem       Date:  1988-08-25       Impact factor: 5.157

3.  Detection of activation of the contact system of coagulation in vitro and in vivo: quantitation of activated Hageman factor-C-1-inhibitor and kallikrein-C-1-inhibitor complexes by specific radioimmunoassays.

Authors:  J H Nuijens; C C Huijbregts; M Cohen; G O Navis; A de Vries; A J Eerenberg; J C Bakker; C E Hack
Journal:  Thromb Haemost       Date:  1987-08-04       Impact factor: 5.249

4.  Inactivation of C-1 inhibitor by proteases: demonstration by a monoclonal antibody of a neodeterminant on inactivated, non-complexed C-1 inhibitor.

Authors:  J H Nuijens; C C Huijbregts; G M van Mierlo; C E Hack
Journal:  Immunology       Date:  1987-07       Impact factor: 7.397

5.  Inhibition of human blood coagulation factor XIa by C-1 inhibitor.

Authors:  J C Meijers; R A Vlooswijk; B N Bouma
Journal:  Biochemistry       Date:  1988-02-09       Impact factor: 3.162

6.  Plasma kallikrein-kinin system in patients with uncomplicated sepsis and septic shock--comparison with cardiogenic shock.

Authors:  F Martínez-Brotóns; J R Oncins; J Mestres; V Amargós; C Reynaldo
Journal:  Thromb Haemost       Date:  1987-08-04       Impact factor: 5.249

7.  Participation and interactions of neutrophil elastase in haemostatic disorders of patients with severe infections.

Authors:  R Seitz; M Wolf; R Egbring; K P Radtke; A Liesenfeld; P Pittner; K Havemann
Journal:  Eur J Haematol       Date:  1987-03       Impact factor: 2.997

8.  Interactions of plasma kallikrein and C1-s with normal and dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema: analytic gel studies.

Authors:  V H Donaldson; C J Wagner; B Tsuei; G Kindness; D H Bing; R A Harrison; F S Rosen
Journal:  Blood       Date:  1987-04       Impact factor: 22.113

9.  Activation of the contact system of plasma proteolysis in the adult respiratory distress syndrome.

Authors:  A C Carvalho; S DeMarinis; C F Scott; L D Silver; A H Schmaier; R W Colman
Journal:  J Lab Clin Med       Date:  1988-08

10.  Primary structure of the reactive site of human C1-inhibitor.

Authors:  G S Salvesen; J J Catanese; L F Kress; J Travis
Journal:  J Biol Chem       Date:  1985-02-25       Impact factor: 5.157

View more
  32 in total

1.  alpha(1)-Proteinase inhibitor mutants with specificity for plasma kallikrein and C1s but not C1.

Authors:  Thomas Sulikowski; Bryan A Bauer; Philip A Patston
Journal:  Protein Sci       Date:  2002-09       Impact factor: 6.725

2.  Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.

Authors:  Angelo Agostoni; Emel Aygören-Pürsün; Karen E Binkley; Alvaro Blanch; Konrad Bork; Laurence Bouillet; Christoph Bucher; Anthony J Castaldo; Marco Cicardi; Alvin E Davis; Caterina De Carolis; Christian Drouet; Christiane Duponchel; Henriette Farkas; Kálmán Fáy; Béla Fekete; Bettina Fischer; Luigi Fontana; George Füst; Roberto Giacomelli; Albrecht Gröner; C Erik Hack; George Harmat; John Jakenfelds; Mathias Juers; Lajos Kalmár; Pál N Kaposi; István Karádi; Arianna Kitzinger; Tímea Kollár; Wolfhart Kreuz; Peter Lakatos; Hilary J Longhurst; Margarita Lopez-Trascasa; Inmaculada Martinez-Saguer; Nicole Monnier; István Nagy; Eva Németh; Erik Waage Nielsen; Jan H Nuijens; Caroline O'grady; Emanuela Pappalardo; Vincenzo Penna; Carlo Perricone; Roberto Perricone; Ursula Rauch; Olga Roche; Eva Rusicke; Peter J Späth; George Szendei; Edit Takács; Attila Tordai; Lennart Truedsson; Lilian Varga; Beáta Visy; Kayla Williams; Andrea Zanichelli; Lorenza Zingale
Journal:  J Allergy Clin Immunol       Date:  2004-09       Impact factor: 10.793

3.  Interstitial collagenase (matrix metalloproteinase-1) expresses serpinase activity.

Authors:  P E Desrochers; J J Jeffrey; S J Weiss
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

Review 4.  A model for the interplay of inflammatory mediators in sepsis--a study in 48 patients.

Authors:  C E Hack; J H Nuijens; R J Strack van Schijndel; J J Abbink; A J Eerenberg; L G Thijs
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

5.  Plasma levels of C1- inhibitor complexes and cleaved C1- inhibitor in patients with hereditary angioneurotic edema.

Authors:  M Cugno; J Nuijens; E Hack; A Eerenberg; D Frangi; A Agostoni; M Cicardi
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

6.  Combined treatment with C1 esterase inhibitor and antithrombin III improves survival in severe acute experimental pancreatitis.

Authors:  H Yamaguchi; H Weidenbach; H Lührs; M M Lerch; G Dickneite; G Adler
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

7.  N-linked glycosylation at Asn3 and the positively charged residues within the amino-terminal domain of the c1 inhibitor are required for interaction of the C1 Inhibitor with Salmonella enterica serovar typhimurium lipopolysaccharide and lipid A.

Authors:  Dongxu Liu; Cort C Cramer; Jennifer Scafidi; Alvin E Davis
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

8.  Expression of human lactoferrin in milk of transgenic mice.

Authors:  G J Platenburg; E P Kootwijk; P M Kooiman; S L Woloshuk; J H Nuijens; P J Krimpenfort; F R Pieper; H A de Boer; R Strijker
Journal:  Transgenic Res       Date:  1994-03       Impact factor: 2.788

9.  Activation of the complement system in baboons challenged with live Escherichia coli: correlation with mortality and evidence for a biphasic activation pattern.

Authors:  J P de Boer; A A Creasey; A Chang; D Roem; A J Eerenberg; C E Hack; F B Taylor
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

Review 10.  Current and emerging management options for hereditary angioedema in the US.

Authors:  Tolly G Epstein; Jonathan A Bernstein
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.